Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 40 (TRAJ40) is a DNA segment encoding one of the **joining (J) segments** involved in the generation of antigen receptor diversity in T cells[1][3][4][5]. As a recombinatorial element, TRAJ40 is not a full protein or receptor itself, but rather a genetic cassette used during the V(D)J recombination that generates the T cell receptor (TCR) alpha chain[1][3][4]. The TRAJ40 segment provides part of the coding information for the variable domain of TCR alpha chains. The TCR, once formed by the correct recombination of variable (V), joining (J), and constant (C) segments, functions as the cell-surface receptor responsible for antigen recognition in T lymphocytes[1][3][4]. **Importantly, TRAJ40 is not a therapeutic target, receptor, enzyme, or structural protein on its own, but a segment in the gene locus that contributes to TCR diversity**[1][3][4][5][6]. No direct drugs, biomarkers, or safety concerns pertain specifically to TRAJ40; instead, the functionality and diseases relate to the assembled TCR complex and T cell biology in general[1][3][4]. TRAJ40 is best classified as a *recombination segment* (a joining region) and not as a protein target or therapeutic molecule[1][3][4][5]. **Summary of errors/limitations:** Your query identifies TRAJ40 as a "target" or "receptor," which is not accurate; it is a recombination J-segment used in constructing the complete TCR alpha chain. It does not function alone and is not targeted by drugs or biomarker assays[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 40 (TRAJ40).